Glioblastoma Treatment Modalities besides Surgery
| Autor: | Yuanqiang Yu, Hao Zhang, Ruizhe Wang, Fan Fan, Jinfang Liu, Tianmeng Luo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Chemotherapy therapy Temozolomide business.industry medicine.medical_treatment Therapeutic effect glioblastoma Immunotherapy Review novel treatment Surgery Radiation therapy Clinical trial 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Oncolytic Virus Therapy Medicine business Epigenetic therapy medicine.drug |
| Zdroj: | Journal of Cancer |
| ISSN: | 1837-9664 |
| Popis: | Glioblastoma multiforme (GBM) is commonly known as the most aggressive primary CNS tumor in adults. The mean survival of it is 14 to 15 months, following the standard therapy from surgery, chemotherapy, to radiotherapy. Efforts in recent decades have brought many novel therapies to light, however, with limitations. In this paper, authors reviewed current treatments for GBM besides surgery. In the past decades, only radiotherapy, temozolomide (TMZ), and tumor treating field (TTF) were approved by FDA. Though promising in preclinical experiments, therapeutic effects of other novel treatments including BNCT, anti-angiogenic therapy, immunotherapy, epigenetic therapy, oncolytic virus therapy, and gene therapy are still either uncertain or discouraging in clinical results. In this review, we went through current clinical trials, underlying causes, and future therapy designs to present neurosurgeons and researchers a sketch of this field. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|